The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and ...

BP's rival, Shell, has expressed interest in a takeover. That would be the least-worst option for Britain’s beleaguered oil ...

SK bioscience’s acquisition of German contract manufacturer IDT Biologika last year was a strategic play to globalize its drug manufacturing footprint and tap into IDT’s century-old client base.

Deal volume fell by 24 per cent to its lowest level since mid-2020, despite predictions of a surge in activity in the wake of the new US administration, according to the latest report ...

Features 29/04/2025 Pharmaceutical giant GSK was single-minded in making its new London HQ a healthy place to work. Paul Milligan sat down with PTS Consulting to explore the winner of the Smart ...

Shares in Haleon, created in a merger of GSK and Pfizer's (PFE.N) consumer healthcare businesses in 2019, fell as much as 1.7% in morning trade, down 0.7% at 330.1 pence by 0730 GMT.

British drugmaker GSK on Friday sold 240 million shares in its consumer healthcare business Haleon at 335 pence per share, raising about 804 million pounds ($1 billion), the company said.

Ingram, who went by Bob, led the British firm GlaxoWellcome through its merger to become GlaxoSmithKline. He joined Glaxo in 1990 and rose to head its U.S. operations, which were based in Research ...

In July 2022, Haleon emerged as an independent global leader in consumer health after its demerger from GlaxoSmithKline (GSK). Thus, with a portfolio of well-known brands including Eno, Iodex ...

GlaxoSmithKline was formed in 2000 with the merger of Glaxo Wellcome and SmithKline Beecham. Previously, the pharmaceutical giants were separate companies of Glaxo, Wellcome, SmithKline, and Beecham.

GSK was previously known as GlaxoSmithKline and it was born in 2000 from the merger of Glaxo Wellcome and SmithKline Beecham. One way to get a very ballpark idea of what GSK's future might look ...